ivWatch announces new executives

Congrats to Gather!
November 7, 2019
Gather coworking space operator plans to open third office in Hampton Roads
January 13, 2020


ivWatch announced that it made three additions to its executive management team, appointing Teresa “Terry” Blevins, Erin Wendell and Paul Stoddard to executive roles.

Blevins is tabbed as the Newport News, Va.–based company’s new CFO, while Wendell is set to become chief marketing officer and Stoddard is the new VP of sales. They will all report directly to ivWatch president & CEO Gary Warren.

“We are thrilled to welcome Terry, Erin and Paul, three senior executives with proven track records and vision to the ivWatch team,” Warren said in a news release. “Collectively, these leaders will complement our talented team at the company, enrich and advance our global presence, drive awareness in the healthcare industry and to consumers, delivering on our mission to provide safety to our patients by reducing the risks associated with IV infiltration.”

Blevins most recently served as interim CFO at Psionic Lidar after she was CFO of Landmark Media Enterprises. The strategic financial planning veteran of more than 30 years will be responsible for the accounting, finance and supply chain functions at ivWatch.

Wendell most recently held the role of senior director of global communications at Under Armour and has been tabbed to lead ivWatch’s strategic vision and direction for global branding and messaging, digital presence, internal and external communications and experiential marketing.

Stoddard, a veteran of more than 30 years in healthcare sales, spent the last 20 years at Philips Healthcare (NYSE:PHG) leading sales teams in ultrasound and emergency care & resuscitation divisions. His role includes overseeing the U.S. sales and clinical divisions, driving growth and new partnerships, revenue and profitability for the ivWatch company.

ivWatch is a medical biosensor technology company developing devices to improve the safety and effectiveness of intravenous therapy. The company’s technology is designed to use optical sensors to detect adverse IV events early to minimize the risk of injury.